405 related articles for article (PubMed ID: 16842188)
41. The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan.
Tseng ST; Tai CH; Li CR; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2015 Jun; 48(3):249-55. PubMed ID: 24184004
[TBL] [Abstract][Full Text] [Related]
42. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.
Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J
Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902
[TBL] [Abstract][Full Text] [Related]
43. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
[TBL] [Abstract][Full Text] [Related]
44. [The mechanism of action of isoniazid. A chemical model of activation].
Bernadou J; Nguyen M; Meunier B
Ann Pharm Fr; 2001 Sep; 59(5):331-7. PubMed ID: 11787427
[TBL] [Abstract][Full Text] [Related]
45. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria.
Kremer L; Dover LG; Morbidoni HR; Vilchèze C; Maughan WN; Baulard A; Tu SC; Honoré N; Deretic V; Sacchettini JC; Locht C; Jacobs WR; Besra GS
J Biol Chem; 2003 Jun; 278(23):20547-54. PubMed ID: 12654922
[TBL] [Abstract][Full Text] [Related]
47. Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.
Encinas L; O'Keefe H; Neu M; Remuiñán MJ; Patel AM; Guardia A; Davie CP; Pérez-Macías N; Yang H; Convery MA; Messer JA; Pérez-Herrán E; Centrella PA; Alvarez-Gómez D; Clark MA; Huss S; O'Donovan GK; Ortega-Muro F; McDowell W; Castañeda P; Arico-Muendel CC; Pajk S; Rullás J; Angulo-Barturen I; Alvarez-Ruíz E; Mendoza-Losana A; Ballell Pages L; Castro-Pichel J; Evindar G
J Med Chem; 2014 Feb; 57(4):1276-88. PubMed ID: 24450589
[TBL] [Abstract][Full Text] [Related]
48. The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance.
Banerjee A; Sugantino M; Sacchettini JC; Jacobs WR
Microbiology (Reading); 1998 Oct; 144 ( Pt 10)():2697-2704. PubMed ID: 9802011
[TBL] [Abstract][Full Text] [Related]
49. Molecular Dynamics Assisted Mechanistic Study of Isoniazid-Resistance against Mycobacterium tuberculosis InhA.
Kumar V; Sobhia ME
PLoS One; 2015; 10(12):e0144635. PubMed ID: 26658674
[TBL] [Abstract][Full Text] [Related]
50. Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity.
Pflégr V; Horváth L; Stolaříková J; Pál A; Korduláková J; Bősze S; Vinšová J; Krátký M
Eur J Med Chem; 2021 Nov; 223():113668. PubMed ID: 34198149
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA.
McNeil MB; Dennison D; Shelton C; Flint L; Korkegian A; Parish T
Tuberculosis (Edinb); 2017 Dec; 107():133-136. PubMed ID: 29050761
[TBL] [Abstract][Full Text] [Related]
52. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic.
Isakova J; Sovkhozova N; Vinnikov D; Goncharova Z; Talaibekova E; Aldasheva N; Aldashev A
BMC Microbiol; 2018 Mar; 18(1):22. PubMed ID: 29566660
[TBL] [Abstract][Full Text] [Related]
53. Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; More UA; Dixit SR; Balmi SV; Kulkarni BG; Ullagaddi G; Lherbet C; Aminabhavi TM
Bioorg Chem; 2017 Dec; 75():181-200. PubMed ID: 28961440
[TBL] [Abstract][Full Text] [Related]
54. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
55. Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis.
Alcaraz M; Sharma B; Roquet-Banères F; Conde C; Cochard T; Biet F; Kumar V; Kremer L
Eur J Med Chem; 2022 Sep; 239():114531. PubMed ID: 35759907
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
[TBL] [Abstract][Full Text] [Related]
57. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates from Xi'an, China.
Zhou A; Nawaz M; Duan Y; Moore JE; Millar BC; Xu J; Yao Y
Microb Drug Resist; 2011 Jun; 17(2):275-81. PubMed ID: 21388297
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis.
Chollet A; Stigliani JL; Pasca MR; Mori G; Lherbet C; Constant P; Quémard A; Bernadou J; Pratviel G; Bernardes-Génisson V
Chem Biol Drug Des; 2016 Nov; 88(5):740-755. PubMed ID: 27301022
[TBL] [Abstract][Full Text] [Related]
59. [Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: new information on old friends].
De La Iglesia AI; Morbidoni HR
Rev Argent Microbiol; 2006; 38(2):97-109. PubMed ID: 17037259
[TBL] [Abstract][Full Text] [Related]
60. Elucidating isoniazid resistance using molecular modeling.
Wahab HA; Choong YS; Ibrahim P; Sadikun A; Scior T
J Chem Inf Model; 2009 Jan; 49(1):97-107. PubMed ID: 19067649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
